Literature DB >> 26493362

How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis.

Tyrone D Cannon1.   

Abstract

Identifying cognitive and neural mechanisms involved in the development of schizophrenia requires longitudinal observation of individuals prior to onset. Here recent studies of prodromal individuals who progress to full psychosis are briefly reviewed in relation to models of schizophrenia pathophysiology. Together, this body of work suggests that disruption in brain connectivity, driven primarily by a progressive reduction in dendritic spines on cortical pyramidal neurons, may represent a key triggering mechanism. The earliest disruptions appear to be in circuits involved in referencing experiences according to time, place, and agency, which may result in a failure to recognize particular cognitions as self-generated or to constrain interpretations of the meaning of events based on prior experiences, providing the scaffolding for faulty reality testing.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26493362      PMCID: PMC4673025          DOI: 10.1016/j.tics.2015.09.009

Source DB:  PubMed          Journal:  Trends Cogn Sci        ISSN: 1364-6613            Impact factor:   20.229


  100 in total

Review 1.  NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; David A Lewis
Journal:  Schizophr Bull       Date:  2012-02-21       Impact factor: 9.306

2.  The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys.

Authors:  Karl-Anton Dorph-Petersen; Joseph N Pierri; James M Perel; Zhuoxin Sun; Allan R Sampson; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

3.  Prodromal Symptom Severity Predicts Accelerated Gray Matter Reduction and Third Ventricle Expansion Among Clinically High Risk Youth Developing Psychotic Disorders.

Authors:  Yoonho Chung; Aron Jacobson; George He; Theo G M van Erp; Sarah McEwen; Jean Addington; Carrie E Bearden; Kristin Cadenhead; Barbara Cornblatt; Daniel H Mathalon; Thomas McGlashan; Diana Perkins; Larry J Seidman; Ming Tsuang; Elaine Walker; Scott W Woods; Robert Heinssen; Tyrone D Cannon
Journal:  Mol Neuropsychiatry       Date:  2015-05-01

4.  Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis.

Authors:  Danielle A Schlosser; Sarah Jacobson; Qiaolin Chen; Catherine A Sugar; Tara A Niendam; Gang Li; Carrie E Bearden; Tyrone D Cannon
Journal:  Schizophr Bull       Date:  2011-08-08       Impact factor: 9.306

5.  Brain mechanisms underlying reality monitoring for heard and imagined words.

Authors:  Eriko Sugimori; Karen J Mitchell; Carol L Raye; Erich J Greene; Marcia K Johnson
Journal:  Psychol Sci       Date:  2014-01-17

6.  Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA.

Authors:  Miran Kenk; Thiviya Selvanathan; Naren Rao; Ivonne Suridjan; Pablo Rusjan; Gary Remington; Jeffrey H Meyer; Alan A Wilson; Sylvain Houle; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

7.  Establishing the onset of psychotic illness.

Authors:  M Beiser; D Erickson; J A Fleming; W G Iacono
Journal:  Am J Psychiatry       Date:  1993-09       Impact factor: 18.112

8.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

Review 9.  Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings.

Authors:  S Navari; P Dazzan
Journal:  Psychol Med       Date:  2009-04-02       Impact factor: 7.723

10.  Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.

Authors:  P Fusar-Poli; R Smieskova; M J Kempton; B C Ho; N C Andreasen; S Borgwardt
Journal:  Neurosci Biobehav Rev       Date:  2013-06-14       Impact factor: 8.989

View more
  53 in total

1.  Changes in symptom content from a clinical high-risk state to conversion to psychosis.

Authors:  Catherine Marshall; Yun Lu; Kristina Lyngberg; Stephanie Deighton; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel Mathalon; Jean Addington
Journal:  Early Interv Psychiatry       Date:  2017-08-03       Impact factor: 2.732

2.  Transient Patterns of Functional Dysconnectivity in Clinical High Risk and Early Illness Schizophrenia Individuals Compared with Healthy Controls.

Authors:  Eva Mennigen; Susanna L Fryer; Barnaly Rashid; Eswar Damaraju; Yuhui Du; Rachel L Loewy; Barbara K Stuart; Vince D Calhoun; Daniel H Mathalon
Journal:  Brain Connect       Date:  2018-07-05

3.  Beyond the "at risk mental state" concept: transitioning to transdiagnostic psychiatry.

Authors:  Patrick D McGorry; Jessica A Hartmann; Rachael Spooner; Barnaby Nelson
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  Effects of autozygosity and schizophrenia polygenic risk on cognitive and brain developmental trajectories.

Authors:  Aldo Córdova-Palomera; Tobias Kaufmann; Francesco Bettella; Yunpeng Wang; Nhat Trung Doan; Dennis van der Meer; Dag Alnæs; Jaroslav Rokicki; Torgeir Moberget; Ida Elken Sønderby; Ole A Andreassen; Lars T Westlye
Journal:  Eur J Hum Genet       Date:  2018-04-27       Impact factor: 4.246

5.  Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28.

Authors:  K Collste; P Plavén-Sigray; H Fatouros-Bergman; P Victorsson; M Schain; A Forsberg; N Amini; S Aeinehband; S Erhardt; C Halldin; L Flyckt; L Farde; S Cervenka
Journal:  Mol Psychiatry       Date:  2017-02-14       Impact factor: 15.992

6.  Juvenile treatment with mGluR2/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3β.

Authors:  Bo Xing; Genie Han; Min-Juan Wang; Melissa A Snyder; Wen-Jun Gao
Journal:  Neuropharmacology       Date:  2018-05-14       Impact factor: 5.250

7.  Complement Gene Expression Correlates with Superior Frontal Cortical Thickness in Humans.

Authors:  Dana M Allswede; Amanda B Zheutlin; Yoonho Chung; Kevin Anderson; Christina M Hultman; Martin Ingvar; Tyrone D Cannon
Journal:  Neuropsychopharmacology       Date:  2017-07-31       Impact factor: 7.853

8.  Juvenile treatment with a novel mGluR2 agonist/mGluR3 antagonist compound, LY395756, reverses learning deficits and cognitive flexibility impairments in adults in a neurodevelopmental model of schizophrenia.

Authors:  Meng-Lin Li; Yelena Gulchina; Sarah A Monaco; Bo Xing; Brielle R Ferguson; Yan-Chun Li; Feng Li; Xi-Quan Hu; Wen-Jun Gao
Journal:  Neurobiol Learn Mem       Date:  2017-02-16       Impact factor: 2.877

9.  Two distinct neuroanatomical subtypes of schizophrenia revealed using machine learning.

Authors:  Ganesh B Chand; Dominic B Dwyer; Guray Erus; Aristeidis Sotiras; Erdem Varol; Dhivya Srinivasan; Jimit Doshi; Raymond Pomponio; Alessandro Pigoni; Paola Dazzan; Rene S Kahn; Hugo G Schnack; Marcus V Zanetti; Eva Meisenzahl; Geraldo F Busatto; Benedicto Crespo-Facorro; Christos Pantelis; Stephen J Wood; Chuanjun Zhuo; Russell T Shinohara; Haochang Shou; Yong Fan; Ruben C Gur; Raquel E Gur; Theodore D Satterthwaite; Nikolaos Koutsouleris; Daniel H Wolf; Christos Davatzikos
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

Review 10.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.